Intra-arterial tenecteplase after successful endovascular therapy increased the likelihood of excellent neurological outcome (modified Rankin Scale 0-1) at 90 days.
No significant difference in symptomatic intracranial hemorrhage or mortality between groups.
Secondary efficacy endpoints did not show significant improvement, suggesting cautious interpretation.
Further large-scale trials are needed to confirm these findings and inform guideline updates.
